Therefore, a challenge for the future will be to develop a new class of LXR ligands that will conserve a gene-specific effect on suppressing GR transcriptional activity, but in a selective manner, targeting LXRβ but not LXRα, as the latter plays an essential role in LXR agonist-mediated development of hypercholesterolemia [52]. This evidence concerns the gene NR1H2 and familial hypercholesterolemia.